Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

TransMedics Group Q3 2026 Results: Net Income $17.1M, Down 29.8% YoY

TransMedics Group reported total revenue of $203.0 million for the third quarter of 2026, a 41% increase year-over-year, driven by growth in both product and service revenue. Net income for the quarter was $17.1 million, down from $24.3 million in the prior year period, primarily due to increased operating expenses in research, development, and clinical trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue203.0143.8
Gross profit118.784.6
Profit before tax24.123.0
Net income17.124.3
EPS (diluted, $ a share)$0.46$0.66

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-29.8%
Revenue, year on year+41.1%
Gross margin58.5%
Operating margin13.9%
Source

10-Q filed with the SEC, NASDAQ: TMDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

TransMedics Group, Inc.: key numbers

Share price
$92.21Close, Nov 16
Market cap
$3.2B
Shares outstanding
34.73MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from TransMedics Group, Inc.

All →
4:15 PM ET Form 4
Insider Selling

TransMedics Group Director James R. Tobin Sells $380K of Stock

James R. Tobin, Director, sold 4,000 shares of TransMedics Group, Inc. at $94.98 a share, worth $380K in total on Nov 9, 2026. Shares held after the trade: 2,922 (-57.8%).

Value
$380K
Shares
4,000
Price
$94.98
Role
Director
Holding change
-57.8%
Trade date
Nov 9, 2026
4:03 PM ET 8-K
Financial Results

TransMedics Group Financial Results

TransMedics reported record third-quarter 2026 revenue of $203.0 million, a 41% increase year-over-year, driven by strong growth in both product and service revenue. The company achieved net income of $17.1 million and raised its full-year 2026 revenue guidance to a range of $764 million to $774 million.

“The third quarter of 2026 was the strongest in TransMedics’ history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.”

Waleed Hassanein, MD, President and Chief Executive Officer

“We enter 2027 with strong momentum and a robust set of growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped heart and lung segments, with two shots on goal in each through OCS and CHOPS.”

Waleed Hassanein, MD, President and Chief Executive Officer
4:30 PM ET Form 4
Insider Buying

TransMedics Group Director David Weill Buys $109K of Stock

David Weill, Director, bought 1,336 shares of TransMedics Group, Inc. at $81.63 a share, worth $109K in total on Sep 11, 2026. Shares held after the trade: 16,392 (+8.9%).

Value
$109K
Shares
1,336
Price
$81.63
Role
Director
Holding change
+8.9%
Trade date
Sep 11, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.